A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies

被引:40
作者
Warnke, Patrick H. [1 ,5 ]
Humpe, Andreas [2 ]
Strunk, Dirk [3 ]
Stephens, Sebastien [1 ]
Warnke, Frauke [4 ,5 ]
Wiltfang, Joerg [5 ]
Schallmoser, Katharina [3 ]
Alamein, Mohammad [1 ]
Bourke, Robert [1 ,6 ]
Heiner, Peter [1 ,6 ]
Liu, Qin [1 ]
机构
[1] Bond Univ, Clem Jones Res Ctr Stem Cells & Tissue Regenerat, Gold Coast, Qld, Australia
[2] Univ Kiel, Dept Med 2, Sect Stem Cell Transplantat & Immunotherapy, Kiel, Germany
[3] Med Univ Graz, Stem Cell Res Unit, Graz, Austria
[4] Griffith Univ, Sch Dent & Oral Hlth, Gold Coast, Qld, Australia
[5] Univ Kiel, Dept Oral & Maxillofacial Surg, Kiel, Germany
[6] Vis Eye Inst, Southport, Qld 4215, Australia
关键词
Human mesenchymal stem cells; MSC; Tissue engineering; Clinically-applicable practice; Regenerative; Regeneration; FCS; Stem cell; Translational; Protocol; FETAL BOVINE SERUM; STROMAL CELLS; BONE-MARROW; CULTURE-CONDITIONS; ANIMAL SERUM; EXPANSION; ALTERNATIVES; GROWTH; SUBSTITUTE; TISSUE;
D O I
10.1016/j.jcms.2012.07.003
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The transplantation of human stem cells seeded on biomaterials holds promise for many clinical applications in cranio-maxillo-facial tissue engineering and regenerative medicine. However, stem cell propagation necessary to produce sufficient cell numbers currently utilizes fetal calf serum (FCS) as a growth supplement which may subsequently transmit animal pathogens. Human platelet lysate (HPL) could potentially be utilized to produce clinical-grade stem cell-loaded biomaterials as an appropriate FCS substitute that is in line with clinically-applicable practice. The goal of this study was to investigate whether HPL can be successfully used to propagate human mesenchymal stem cells (HMSCs) seeded on clinically-approved collagen materials under clinically-applicable conditions using FCS as a control. HMSCs were isolated from bone marrow and cultured in the presence of 10% FCS or 10% HPL. Characterization of HMSCs was performed by flow cytometry and through osteogenic and adipogenic differentiation assays. Proliferative capacity of HMSCs on both matrices was investigated by mitochondrial dehydrogenase assays (WST) and tissue coverage scanning electron microscopy (SEM). The isolated HMSC differentiated into osteogenic and adipogenic cells authenticating the multi-potentiality of the HMSCs. WST tests and the SEM images demonstrated that HPL was generally superior to FCS in promoting growth of seeded HMSCs. For all other tests HPL supported HMSCs at least equal to FCS. In conclusion, HPL is an effective growth factor to allow expansion of clinical-grade HMSCs on clinically-approved biomaterials for maxillofacial and oral implantology applications. (C) 2012 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:153 / 161
页数:9
相关论文
共 24 条
[1]  
Baba K, J CRANIOMAX IN PRESS
[2]   Two steps to functional mesenchymal stromal cells for clinical application [J].
Bartmann, Christina ;
Rohde, Eva ;
Schallmoser, Katharina ;
Puerstner, Peter ;
Lanzer, Gerhard ;
Linkesch, Werner ;
Strunk, Dirk .
TRANSFUSION, 2007, 47 (08) :1426-1435
[3]  
Berridge M.V., 1996, Biochemica, P14, DOI DOI 10.1155/2013/420601
[4]   Human Alternatives to Fetal Bovine Serum for the Expansion of Mesenchymal Stromal Cells from Bone Marrow [J].
Bieback, Karen ;
Hecker, Andrea ;
Kocaoemer, Asli ;
Lannert, Heinrich ;
Schallmoser, Katharina ;
Strunk, Dirk ;
Klueter, Harald .
STEM CELLS, 2009, 27 (09) :2331-2341
[5]   The primordium of a biological joint replacement: Coupling of two stem cell pathways in biphasic ultrarapid compressed gel niches [J].
Brady, Mariea A. ;
Sivananthan, Sureshan ;
Mudera, Vivek ;
Liu, Qin ;
Wiltfang, Joerg ;
Warnke, Patrick H. .
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2011, 39 (05) :380-386
[6]   Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts [J].
Capelli, C. ;
Domenghini, M. ;
Borleri, G. ;
Bellavita, P. ;
Poma, R. ;
Carobbio, A. ;
Mico, C. ;
Rambaldi, A. ;
Golay, J. ;
Introna, M. .
BONE MARROW TRANSPLANTATION, 2007, 40 (08) :785-791
[7]   Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification [J].
Carrancio, Soraya ;
Lopez-Holgado, Natalia ;
Sanchez-Guijo, Fermin M. ;
Villaron, Eva ;
Barbado, Victoria ;
Tabera, Soraya ;
Diez-Campelo, Maria ;
Blanco, Juan ;
San Miguel, Jesuis F. ;
Consuelo del Canizo, M. .
EXPERIMENTAL HEMATOLOGY, 2008, 36 (08) :1014-1021
[8]  
Castaño O, 2012, METHODS MOL BIOL, V811, P127, DOI 10.1007/978-1-61779-388-2_9
[9]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[10]   Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications [J].
Doucet, C ;
Ernou, I ;
Zhang, YZ ;
Llense, JR ;
Begot, L ;
Holy, X ;
Lataillade, JJ .
JOURNAL OF CELLULAR PHYSIOLOGY, 2005, 205 (02) :228-236